Kymera Therapeutics (KYMR) Misses Q2 EPS by 8c

Kymera Therapeutics (NASDAQ: KYMR) reported Q2 EPS of ($0.78), $0.08 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $11.51 million versus the consensus estimate of $13.84 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• Kymera Therapeutics (KYMR) PT Raised to $170 at Guggenheim
• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• Herbalife reaffirms Q3 and full-year 2026 financial guidance